Related Experiment Videos
Invasive aspergillosis
B Dupont1, M Richardson, P E Verweij
1Unité de Mycologie, Institut Pasteur, H pital Necker, Paris, France. bdupont@pasteur.fr
Abstract:
Acute invasive aspergillosis (IA) is a devastating disease. Early diagnosis allowing an early treatment may improve the prognosis. However, this goal remains difficult to achieve. When diagnosis is confirmed it is often already too late. Galactomannan antigen detection and DNA detection are under clinical evaluation to improve early diagnosis and management of treatment. Despite antifungal treatment mortality rate is still high. Clinical resistance is more often due to the intensity of immunodepression than to high minimum inhibitory concentrations to antifungal agents; however, resistance to itraconazole may occur in rare instances. Beside acute IA, a chronic form of this infection may be seen as chronic necrotizing pulmonary aspergillosis or chronic invasive sinusitis. Other sites of infection have been described. The patients are immunocompetent or present minor alteration of their immunity or of anatomic structure of the infected site. Among patients with solid organ transplantation, lung and liver transplant patients are at the highest risk of developing IA. A high degree of awareness and efforts for an early diagnosis may participate to improve the poor prognosis.
Insights
Early diagnosis of invasive aspergillosis (IA) is crucial but challenging. New antigen and DNA detection methods show promise for improving outcomes in this devastating fungal infection.
Area of Science:
- Mycology
- Infectious Diseases
- Clinical Diagnostics
Background:
- Acute invasive aspergillosis (IA) is a severe and often fatal fungal infection.
- Current diagnostic methods often confirm IA late, hindering timely treatment and improving patient prognosis.
- High mortality rates persist despite antifungal therapies, underscoring the need for earlier detection.
Purpose of the Study:
- To highlight the challenges in early diagnosis of invasive aspergillosis.
- To discuss emerging diagnostic tools like galactomannan antigen and DNA detection.
- To emphasize the importance of early detection for improving patient outcomes.
Main Methods:
- Review of current diagnostic approaches for invasive aspergillosis.
- Evaluation of novel biomarkers such as galactomannan antigen and fungal DNA.
- Analysis of factors contributing to treatment resistance and patient risk groups.
Main Results:
- Early diagnosis of IA remains difficult, with confirmation often occurring when the disease is advanced.
- Galactomannan antigen and DNA detection are under clinical evaluation for improved early diagnosis.
- High mortality is associated with severe immunodepression, though rare antifungal resistance can occur.
Conclusions:
- Improved diagnostic strategies, including antigen and DNA detection, are essential for earlier IA diagnosis.
- Awareness and prompt diagnosis are critical for improving the prognosis of invasive aspergillosis, particularly in high-risk transplant patients.
- While antifungal resistance is uncommon, understanding patient immunodeficiency is key to managing IA effectively.